Business Context and Reporting Period
Company: Klotho Neurosciences, Inc. (formerly ANEW Medical, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: The Company is a pre-revenue biopharmaceutical entity developing essential medicines for chronic diseases, including cancer, cardiovascular, and neurodegenerative disorders. It operates a single segment focused on a generic drug portfolio, a biosimilar biologics platform, and a proprietary gene therapy platform targeting the "Klotho" protein.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(2,895,585) | $(9,222,798) | $(4,083,109) |
| Operating Expenses | $1,853,304 | $5,333,124 | $3,688,584 |
| Interest Expense | $1,177,999 | $3,491,961 | $60,020 |
| Cash and Equivalents (End of Period) | $7,348,034 | $7,348,034 | $50,895 |
| Net Working Capital | $7,680,699 | $7,680,699 | N/A |
| Total Liabilities | $145,891 | $145,891 | $1,272,020 |
| Accumulated Deficit | $(19,785,597) | $(19,785,597) | $(8,495,536) |
Material Changes vs. Prior Period
- Liquidity Surge: Cash and cash equivalents increased from $63,741 at year-end 2024 to $7.35 million at September 30, 2025. This was driven by net cash provided by financing activities of $11.9 million, primarily from warrant exercises ($11.4 million) and convertible note proceeds.
- Debt Reduction: Total liabilities decreased significantly from $1.27 million to $145,891. The Company paid off or converted all outstanding notes payable (including Austria Capital and 3i LP notes) and related party notes during the period.
- Expense Volatility: Net loss for the nine months ended September 30, 2025, more than doubled compared to the prior year ($9.2M vs. $4.1M). This increase was driven by a massive spike in interest expense ($3.5M vs. $60k) due to debt conversions and amortization of original issue discounts, partially offset by a decrease in share-based compensation.
- Capital Structure: Common shares outstanding increased from 27.1 million (Dec 31, 2024) to 70.3 million (Sep 30, 2025) due to warrant exercises, debt conversions, and private placements.
Outlook, Risks, and Contingencies
- Going Concern: Management has expressed substantial doubt about the Company's ability to continue as a going concern for twelve months without additional funding. The Company relies on equity or debt sales to fund operations.
- NASDAQ Compliance: The Company received a delinquency notification on September 19, 2025, for failing to maintain a $1.00 minimum bid price. It has 180 days (until March 18, 2026) to regain compliance.
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting as of December 31, 2024, citing inadequate accounting resources and lack of segregation of duties. Remediation efforts were initiated by September 30, 2025.
- Acquisition Termination: The Company terminated a Share Exchange Agreement to acquire SB Security Holdings, LLC on June 13, 2025.
- Subsequent Events: Post-period, the Company settled additional At-The-Market sales for approximately $1.08 million in net proceeds.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $7.35 million cash balance against the current operating burn rate (approx. $4.6M used in operations for 9 months).
- Debt Conversion Terms: Review the specific terms of the debt-to-equity conversions that generated significant interest expense and dilution in Q3 2025.
- NASDAQ Compliance Plan: Assess the likelihood of the stock price recovering to $1.00 within the 180-day compliance window.
- Revenue Timeline: Confirm the projected timeline for the commercialization of the generic drug and biosimilar platforms, as the company remains pre-revenue.
- Internal Control Remediation: Monitor future filings for confirmation that the material weaknesses in internal controls have been fully remediated.